Plant Summary
Plant Information
TCMBank_ID: | TCMBANKHE003898 |
ID: | TCMBANKHE003898 |
植物拉丁名: |
|
功能与主治: | See Lycopodium japonicum./See Lycopodium japonicum. |
药用植物名: | 铺地蜈蚣 |
药用部位: | whole plant |
TCM_ID_id: | 6967 |
植物对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN000541 | lycernuicketone a | C31H48O6 | 516.7 g/mol | CC12CCC3C(C1CCC4C(=CC(=O)C5C4(CCC(C5(C)CO)O)C)C2)(CCC(C3(C)C(=O)OC)O)C | |
| TCMBANKIN000962 | campesterol | campesterol ; FT-0082089; Augelicincampesterol; (24R)-5-Ergosten-3; (1R,3AS,3BR,9AS,9BS,11AR)-1-[(2R,5R)-5,6-DIMETHYLHEPTAN-2-YL]-9A,11A-DIMETHYL-1H,2H,3H,3AH,3BH,4H,5H,5AH,6H,9H,9BH,10H,11H-CYCLOPENTA[A]PHENANTHREN-7-OL; A-ol; 24(R)-Ergost-5-en-3beta-ol; 24alpha-Methyl-5-cholesten-3beta-ol; AK307302; SC-66911; (8R,9S,10S,13R,14S,17R)-17-((2R,5R)-5,6-Dimethylheptan-2-yl)-10,13-dimethyl-4,5,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol; AKOS027320474; MFCD00010475; Campesterin; MolPort-035-882-175 | C28H48O | 400.68 | CC(C)C(C)CCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C |
| TCMBANKIN001097 | cernuoside c | C53H86O22 | CC1C(C(C(C(O1)OC2C(C(C(OC2OC3COC(C(C3O)O)OC4CCC5(C(C4(C)CO)CCC6(C5CC=C7C6(CCC8(C7CC(CC8)(C)C)C(=O)OC9C(C(C(C(O9)CO)O)O)O)C)C)C)CO)O)O)O)O)O | ||
| TCMBANKIN006794 | lycernuicketone b | C31H48O6 | 516.7 g/mol | CC12CCC3C(C1CCC4C(=CC(=O)C5C4(CCC(C5(C)CO)O)C)C2)(CCC(C3(C)C(=O)OC)O)C | |
| TCMBANKIN010970 | lycernuicacid b | C30H48O5 | CC12CCC3C(C1CCC4C(=CCC5C4(CCC(C5(C)CO)O)C)C2)(CCC(C3(C)C(=O)O)O)C | ||
| TCMBANKIN011303 | 21-episerratriol | C30H50O3 | 458.7 g/mol | CC1(C(CCC2(C1CC=C3C2CCC4C(C3)(CCC5C4(CCC(C5(C)CO)O)C)C)C)O)C | |
| TCMBANKIN014618 | Campesteryl ferulate | campesteryl ferulate | C38H56O4 | 576.85 | CC(C)C(C)CCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)OC(=O)C=CC5=CC(=C(C=C5)O)OC)C)C |
| TCMBANKIN018728 | alpha-onocerin | (2S,4aR,5S,8aR)-5-{2-[(1S,4aR,6S,8aR)-6-hydroxy-5,5,8a-trimethyl-2-methylenedecahydronaphthalen-1-yl]ethyl}-1,1,4a-trimethyl-6-methylenedecahydronaphthalen-2-ol; MolPort-006-111-540; GESZMTVZGWZBPW-IHIDZKKCSA-; 2-Naphthalenol,5,5'-(1,2-ethanediyl)bis[decahydro-1,1,4a-trimethyl-6-methylene-,(2S,2'S,4aR,4'aR,5S,5'S,8aR,8'aR)-; 8,14-secogammacera-8(26),14(27)-diene-3beta,21alpha-diol; (3beta,21alpha)-8,14-Secogammacera-8(26),14(27)-diene-3,21-diol; ZINC38605938; alpha-Onocerol; α-onocerin; C21734; Alpha-onocerin, primary pharmaceutical reference standard; CHEBI:138303; (2S,4AR,5S,8AR)-5-{2-[(1S,4AR,6S,8AR)-6-HYDROXY-5,5,8A-TRIMETHYL-2-METHYLIDENE-HEXAHYDRO-1H-NAPHTHALEN-1-YL]ETHYL}-1,1,4A-TRIMETHYL-6-METHYLIDENE-HEXAHYDRO-2H-NAPHTHALEN-2-OL; MCULE-4277793393; EINECS 208-118-6; W2391; 511-01-3; InChI=1/C30H50O2/c1-19-9-13-23-27(3,4)25(31)15-17-29(23,7)21(19)11-12-22-20(2)10-14-24-28(5,6)26(32)16-18-30(22,24)8/h21-26,31-32H,1-2,9-18H2,3-8H3/t21-,22-,23-,24-,25-,26-,29+,30+/m0/s1; alpha-Onocerin; SC-97924; (+)-alpha-onocerin | C30H50O2 | 442.7 g/mol | CC1(C2CCC(=C)C(C2(CCC1O)C)CCC3C(=C)CCC4C3(CCC(C4(C)C)O)C)C |
| TCMBANKIN020728 | lycernuicacid c | C30H50O7 | 522.7 g/mol | CC12CCC3C(C1CCC4C5(CCC(C(C5CC(C4(C2)O)O)(C)CO)O)C)(CCC(C3(C)C(=O)O)O)C | |
| TCMBANKIN020792 | lycoclavanin | C30H48O5 | 488.7 g/mol | CC1(C(C(CC2(C1C(=O)CC3=CC4(CCC5C(C4CCC32)(CCC(C5(C)CO)O)C)C)C)O)O)C | |
| TCMBANKIN024863 | cernuine | C16H26N2O | 262.39 g/mol | CC1CC2CCCC3N2C(C1)CC4N3C(=O)CCC4 | |
| TCMBANKIN025354 | serratumin a | C16H22O8 | CC(=CCCC(=C)C1COC2C1(C(=O)C(C(O2)CO)O)O)C(=O)O | ||
| TCMBANKIN032501 | lycocernuine | C16H26N2O2 | 278.39 g/mol | CC1CC2CC3CCCC(=O)N3C4N2C(C1)C(CC4)O | |
| TCMBANKIN034071 | cernoside | C39H32O14 | C1=CC(=CC=C1C=CC(=O)OCC2C(C(C(C(O2)OC3=CC(=C4C(=C3)OC(=CC4=O)C5=CC=C(C=C5)O)O)O)O)OC(=O)C=CC6=CC=C(C=C6)O)O | ||
| TCMBANKIN034258 | lycernuicacid d | C30H50O6 | 506.7 g/mol | CC1(C(CCC2(C1CC(C3(C2CCC4C(C3)(CCC5C4(CCC(C5(C)C(=O)O)O)C)C)O)O)C)O)C | |
| TCMBANKIN035372 | lycernuicacid e | C30H50O5 | 490.7 g/mol | CC1(C2CCC3(CC4(CCC5C(C4CCC3C2(CCC1O)C)(CCC(C5(C)C(=O)O)O)C)C)O)C | |
| TCMBANKIN037131 | ononin | 4H-1-Benzopyran-4-one, 7-(beta-D-glucopyranosyloxy)-3-(4-methoxyphenyl)-; MEGxp0_000395; 3-(4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one; LMPK12050014; 486-62-4; 3-(4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-chromen-4-one; 3-(4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-methylol-tetrahydropyran-2-yl]oxy-chromone; Formononetin glucoside; STOCK1N-14986; 75375_FLUKA; 3-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl beta-D-glucopyranoside; ACon1_000463; ZINC01081322; 3-(4-methoxyphenyl)-7-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-tetrahydropyranyl]oxy]-4-chromenone; CHEBI:7775; 3-(4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-chromen-4-one; Ononin; C10509; Formononetin 7-O-glucoside; Formononetin-7-O-beta-D-glucopyranoside; Formononetin-7-glucoside | C22H22O9 | 430.405 | [C@@]1([H])(O[H])[C@]([H])(C([H])([H])O[H])O[C@]([H])(Oc2c([H])c([H])c(C(=O)C(c3c([H])c([H])c(OC([H])([H])[H])c([H])c3[H])=C([H])O4)c4c2[H])[C@@]([H])(O[H])[C@]1([H])O[H] |
| TCMBANKIN039206 | apigenin-4'-o-(2',6''-di-o-p-coumaroyl)-β-d-glucoside | C39H32O14 | C1=CC(=CC=C1C=CC(=O)OCC2C(C(C(C(O2)OC3=CC=C(C=C3)C4=CC(=O)C5=C(C=C(C=C5O4)O)O)OC(=O)C=CC6=CC=C(C=C6)O)O)O)O | ||
| TCMBANKIN059028 | serratenediol-3-acetate | 21α-hydroxyserrat-14-en-3β-yl acetate | C32H52O3 | CC(=O)OC1CCC2(C3CCC4C(=CCC5C4(CCC(C5(C)C)O)C)CC3(CCC2C1(C)C)C)C | |
| TCMBANKIN059207 | Epishyobunone | epishyobunone; (2R,3S,6S)-3-ethenyl-3-methyl-6-propan-2-yl-2-prop-1-en-2-ylcyclohexan-1-one; (2R,3S,6S)-2-isopropenyl-6-isopropyl-3-methyl-3-vinyl-cyclohexan-1-one; (2R,3S,6S)-3-ethenyl-3-methyl-6-propan-2-yl-2-prop-1-en-2-yl-cyclohexan-1-one; (2R,3S,6S)-2-isopropenyl-6-isopropyl-3-methyl-3-vinyl-1-cyclohexanone (2S,3S,6S)-3-ETHENYL-6-ISOPROPYL-3-METHYL-2-(PROP-1-EN-2-YL)CYCLOHEXAN-1-ONE; MolPort-035-706-214; (2S,3S,6S)-3-ethenyl-3-methyl-6-propan-2-yl-2-prop-1-en-2-yl-cyclohexan-1-one; (+)-Shyobunone; CHEMBL1814552; BG00930849; W2226; (2S,3S,6S)-3-ethenyl-3-methyl-6-propan-2-yl-2-prop-1-en-2-ylcyclohexan-1-one; (2S,3S,6S)-2-isopropenyl-6-isopropyl-3-methyl-3-vinyl-1-cyclohexanone; AKOS032962114; SHYOBUNONE; CHEBI:68148; 21698-44-2; shyobunone; AC1NT0E3; (2S,3S,6S)-2-isopropenyl-6-isopropyl-3-methyl-3-vinyl-cyclohexan-1-one; ZINC15150042;Shyobunone | C15H24O | 220.35 | CC(C)C1CCC(C(C1=O)C(=C)C)(C)C=C |
| TCMBANKIN059463 | lycernuicketone c | C30H48O4 | 472.7 g/mol | CC1(C(CCC2(C1C(=O)C=C3C2CCC4C(C3)(CCC5C4(CCC(C5(C)CO)O)C)C)C)O)C | |
| TCMBANKIN059468 | lycernuic acid A | C30H48O4 | 472.7 g/mol | CC1(C(CCC2(C1CC=C3C2CCC4C(C3)(CCC5C4(CCC(C5(C)C(=O)O)O)C)C)C)O)C | |
| TCMBANKIN059469 | 21-episerratriol | C30H50O3 | 458.7 g/mol | CC1(C(CCC2(C1CC=C3C2CCC4C(C3)(CCC5C4(CCC(C5(C)CO)O)C)C)C)O)C | |
| TCMBANKIN059548 | 21-episerratenediol | C30H50O2 | 442.7 g/mol | CC1(C2CCC3(CC4=CCC5C(C(CCC5(C4CCC3C2(CCC1O)C)C)O)(C)C)C)C | |
| TCMBANKIN060679 | stigmasterol | C29H48O | 412.7 g/mol | CCC(C=CC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C)C(C)C | |
| TCMBANKIN060680 | stigmasterol-3-glucoside | C35H58O6 | 574.83 g/mol | CCC(C=CC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)OC5C(C(C(C(O5)CO)O)O)O)C)C)C(C)C | |
| TCMBANKIN061371 | nicotine | 36733_RIEDEL; 2yk1; CHEBI:59806; 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine; (2S)-1-methyl-2-(pyridin-3-yl)pyrrolidinium; (S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE; D03365; 54-11-5; NCGC00090693-03; 46343_RIEDEL; C00745; Nicotine; NCGC00090693-04; AIDS-156031; 65-31-6 (R,R-BITARTRATE); (2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine; (S)-3-(N-methylpyrrolidin-2-yl)pyridine; Habitrol (TN); SBB012359; N5511_SIGMA; (−)-Nicotine; Nicotine (compounds related to); PDSP2_000555; NCT; N3876_SIGMA; 3-[(2S)-1-methyl-2-pyrrolidinyl]pyridine; NCGC00090693-01; ZB012057; (S)-(-)-nicotine; CHEBI:17688; SDCCGMLS-0066911.P001; (S)-nicotinium(1+); AC1OCG5J; 3-(2-(N-methylpyrrolidinyl))pyridine; NSC97238 (R,R-BITARTRATE SALT); 3-[(2S)-1-methylpyrrolidin-1-ium-2-yl]pyridine; (S)-nicotinium cation; AIDS156031; NCGC00090693-05; PDSP1_000465; PDSP1_000113; PDSP2_000463; (S)-3-(1-methylpyrrolidin-2-yl)pyridine; Nicotine (USP); 54-11-5 (FREE BASE); L(-)-nicotine; (−)-Nicotine solution | C10H14N2 | 162.23 g/mol | CN1CCCC1C2=CN=CC=C2 |
| TCMBANKIN061841 | Calycosin-7-0-β-D-glucopyranoside | 4H-1-Benzopyran-4-one, 7-(beta-D-glucopyranosyloxy)-3-(4-methoxyphenyl)-; MEGxp0_000395; 3-(4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one; LMPK12050014; 486-62-4; 3-(4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-chromen-4-one; 3-(4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-methylol-tetrahydropyran-2-yl]oxy-chromone; Formononetin glucoside; STOCK1N-14986; 75375_FLUKA; 3-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl beta-D-glucopyranoside; ACon1_000463; ZINC01081322; 3-(4-methoxyphenyl)-7-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-tetrahydropyranyl]oxy]-4-chromenone; CHEBI:7775; 3-(4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-chromen-4-one; Ononin; C10509; Formononetin 7-O-glucoside; Formononetin-7-O-beta-D-glucopyranoside; Formononetin-7-glucoside; ononin | C22H22O9 | 430.4 | COC1=CC=C(C=C1)C2=COC3=C(C2=O)C=CC(=C3)OC4C(C(C(C(O4)CO)O)O)O |
植物对应的疾病
| 疾病ID | 病名 | 疾病类型 | MeSH | 参考文献 |
|---|
植物对应的靶点
| 靶点ID | 基因名 | 基因别名 | 描述 | 染色体位置 | Map_Location | 基因类型 |
|---|
滇ICP备16009434号-1 |
Dai SX Lab